Source: http://neidos.it/index.pl?pos=03.01&ids=349
Timestamp: 2019-04-22 18:16:32+00:00

Document:
1962-67: Attended the Scientific Lyceum in Ferrara, Italy (Diploma).
1974: National Medical Board Exam (National License).
1972: Visiting Medical Student, University of Chicago Medical School, Chicago, IL.
1975-76: M.D. Lieutenent, Italian Army Medical Corp.
1977: Assistant Professor, Institute of Medical Genetics, University of Torino Medical School.
1978-79: Visiting Assistant Professor, Department of Medical Genetics, Mount Sinai School of Medicine, New York, N.Y.
1979: Visiting Scientist, Basel Institute for Immunology, Basel, Switzerland.
1982: Visiting Scientist, Sloan-Kettering Cancer Center, New York, N.Y.
1982: Associate Professor of Cell Biology, University of Torino Medical School, Italy.
1985: Visiting Scientist, Lab of Cellular and Molecular Biology, Beth Israel Hospital, New York, N.Y.
1994: Professor of Cell Biology, University of Ancona Medical School.
2000-today: Professor of Medical Genetics, University of Torino Medical School, Torino, Italy.
- Analysis of cell surface differentiation molecules expressed by human leukocytes in health and tumor conditions and during organ transplantation.
- Analysis of ectoenzyme network in positive and negative regulations of effector activities of human leukocyte subsets.
- Analysis of tumor antigens or tumor-associated molecules as targets for antibody-mediated interventions.
- Member of the Board of National Experts on Biomedical Science, Italian Ministry of Public Health, 2001- 2003.
- Councillors Board, The Human Leukocyte Differentiation Antigens/HCDM, 2005 - today.
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.
CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.
CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.
334) S. Rasi, V. Spina, A. Bruscaggin, T. Vaisitti, C. Tripodo, F. Forconi, L. Depaolo, M. Fangazio, E. Sozzi, E. Cencini, L. Laurenti, R. Marasca, C. Visco, ZY Xu-Monette, V. Gattei, KH Young, F. Malavasi, S. Deaglio, D. Rossi and G. Gaidano.
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.
335) A. Pezzolo, F. Parodi, D. Marimpietri, L. Raffaghello, C. Cocco, A. Pistorio, M. Mosconi, C. Gambini, M. Cilli, S. Deaglio, F. Malavasi, and V. Pistoia.
OCT-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells.
EA2 is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia.
A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia (CLL) cells and tumor microenvironment.
339) S. Sandini, R. La Valle, S. Deaglio, F. Malavasi, A. Cassone, F. De Bernardis.
340) R.P. Ebstein, D. Mankuta, N. Yirmiya and F. Malavasi.
Are retinoids potential therapeutic agents in disorders of social cognition including autism?
CD38 and retinoids: a step toward a cure.
342) M. Riebold, D. Mankuta, E. Lerer, S. Israel, S. Zhong, L. Nemanov, M.V. Monakhov, S. Levi, N. Yirmiya, M. Yaari, F. Malavasi and R. Ebstein.
All-trans-Retinoic-Acid (ATRA) upregulates reduced CD38 transcription in lymphoblastoid cell lines from autism spectrum disorder.
343) E. Ferretti, M. Bertolotto, S. Deaglio, C. Tripodo, D. Ribatti, V. Audrito, F. Blengio, S. Matis, S. Zupo, D. Rossi, L. Ottonello, G. Gaidano, F. Malavasi, V. Pistoia and A. Corcione.
A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment.
344) V. Audrito, T. Vaisitti, D. Rossi, D. Gottardi, G. D"Arena, L. Laurenti, G. Gaidano, F. Malavasi and S. Deaglio.
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
345) S. Deaglio, T. Vaisitti, S. Serra, V. Audrito, C. Bologna, G. D"Arena, L. Laurenti, D. Gottardi and F. Malavasi.
CD38 in chronic-lymphocytic leukemia: from bench to bedside?
346) F. Malavasi, S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini, N. Chiorazzi.
CD38 and chronic lymphocytic leukemia: a decade later.
The aim of our research Project is to exploit miRNAs as drugs or targets in innovative therapeutic strategies for Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) based on biological driven hypothesis, novel in vitro and in vivo preclinical models and delivery nanotechnologies.
The experimental design includes production and characterization of monoclonal antibodies for target identification, scale-up of the production of clinical grade antibodies, bioreagent development, validation in in vitro appropriate cellular system and preclinical studies.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.